Like I've said before there is a bit too much blind emphasis on FDA approval being some watershed moment and major catalyst for BUB.
I agree more with your point that it is baked in, with little tangible impact on sales.
BUB has to de-emphasise USA and re-emphasise China.
The China revenue segment will be drawing much closer to that of USA by the end of this FY and will overtake USA in the next FY.
And there is much more upside in China in terms of potential growth. My concern remains that management is still disproportionately fixated on USA and unprepared to capitalise on China. Any takeover won't come from USA, it will come from China. USA remains a heavily protected domestic monopoly in terms of infant formula, so it will always be a major uphill battle to keep revenues growing.
BUB Price at posting:
13.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)